Appropriate Use and Interpretation of Cardiac Biomarkers Dr. Vikas - - PowerPoint PPT Presentation

appropriate use and interpretation of cardiac biomarkers
SMART_READER_LITE
LIVE PREVIEW

Appropriate Use and Interpretation of Cardiac Biomarkers Dr. Vikas - - PowerPoint PPT Presentation

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON Appropriate Use and Interpretation of Cardiac Biomarkers Dr. Vikas Tandon Associate Professor, Cardiology McMaster University November 1, 2017 CSIM Annual Meeting 2017


slide-1
SLIDE 1

Appropriate Use and Interpretation of Cardiac Biomarkers

  • Dr. Vikas Tandon

Associate Professor, Cardiology McMaster University November 1, 2017

Canadian Society of Internal Medicine

Annual Meeting 2017

Toronto, ON

slide-2
SLIDE 2

CSIM Annual Meeting 2017

Conflict Disclosures

I have the following conflicts to declare:

Company/Organization Details Advisory Board or equivalent

X

X

Speakers bureau member

X

X

Payment from a commercial organization. (including gifts or other consideration or ‘in kind’ compensation)

X

X

Grant(s) or an honorarium

X

X

Patent for a product referred to or marketed by a commercial organization.

X

X

Investments in a pharmaceutical

  • rganization, medical devices company or

communications firm.

X

X

Participating or participated in a clinical trial

McMaster University

Participated in periop research studies including VISION, POISE-2, MANAGE

slide-3
SLIDE 3

CSIM Annual Meeting 2017

The following presentation represents the views of the speaker at the time of the presentation. This information is meant for educational purposes, and should not replace other sources

  • f information or your medical judgment.

Learning Objectives:

  • Develop an approach to managing patients elevated troponins who

present with non-coronary presentations

  • Develop short- and long-term management plans for patients with

post-operative troponin elevations

  • Understand the indications for ordering a BNP in acute medical

patients and interpret results

slide-4
SLIDE 4

Perioperative Care Congress: Science, Evidence and Practice

Save the date: Perioperative Care Congress 2018 May 11-13, 2018 Toronto, Ontario CANADA Visit our website http://periopcongress.org/

  • r follow us on twitter @periopcongress

More information to follow!

slide-5
SLIDE 5
  • Biomarkers are commonly used in medical

patients as a means to diagnosis and prognosis

  • Biomarkers very sensitive but not necessarily

specific for any one particular disease process

  • Interpretation can sometimes be challenging thus

requiring an organized approach

Scope of problem

slide-6
SLIDE 6
  • 66 F presents with 8/10 RSCP, diaphoresis, palpitations
  • Baseline ECG shows rapid atrial fibrillation on admission
  • Cardiac RF – DM, HTN, dyslipidemia, remote smoker
  • Meds: ASA 81 mg, Rosuvastatin 10 mg, Perindopril 8 mg,

Metoprolol 50 mg BID

  • O/E – HR 120-140 bpm, BP 130/78; otherwise normal
  • hs-trop I 620 (peak)

Case 1

slide-7
SLIDE 7

12 Lead

slide-8
SLIDE 8
  • 1. Normal coronaries
  • 2. Mild atherosclerotic plaque with no significant stenosis
  • 3. Single vessel disease
  • 4. Multivessel disease

This patient has:

slide-9
SLIDE 9
  • 50 F presents with 2 day history of headaches, chest and back pain

lasting hours at a time

  • Cardiac RF – HTN, current smoker (30 pack year history)
  • O/E – Hypertensive urgency with BP 200/118 on admission, HR 67;

symptoms resolved when normotensive in hospital

  • hs-trop I 68 (peak)

Case 2

slide-10
SLIDE 10

12 Lead

slide-11
SLIDE 11
  • 1. Normal coronaries
  • 2. Mild atherosclerotic plaque with no significant stenosis
  • 3. Single vessel disease
  • 4. Multivessel disease

This patient has:

slide-12
SLIDE 12
  • 58 F presents with bright red blood per rectum, known history of

Ulcerative Colitis

  • Cardiac RF – HTN, 40 pack year smoking history (recently quit)
  • No cardiac symptoms. O/E – HR 110-120, BP 130/78
  • hs-trop I 108 (peak), Hb 118 (stable)

Case 3

slide-13
SLIDE 13

12 Lead

slide-14
SLIDE 14
  • 1. Normal coronaries
  • 2. Mild atherosclerotic plaque with no significant stenosis
  • 3. Single vessel disease
  • 4. Multivessel disease

This patient has:

slide-15
SLIDE 15

The cases thus far:

Case 1 Case 2 Case 3 66 F w 8/10 RSCP rapid A Fib 120-140 50 F headaches, CP and back pain lasting hours HTN urgency: BP 200/118 58 F bright red blood per rectum; known UC DM, HTN, Chol, remote smoker (5 pack yr history) HTN, current smoker (30 pack year history) HTN, recent smoker (40 pack year history) Peak trops = 620 Peak trops = 68 Peak trops = 108

slide-16
SLIDE 16

The cases thus far:

Case 1 Case 2 Case 3 66 F w 8/10 RSCP rapid A Fib 120-140 50 F headaches, CP and back pain lasting hours HTN urgency: BP 200/118 58 F bright red blood per rectum; known UC DM, HTN, Chol, remote smoker (5 pack yr history) HTN, current smoker (30 pack year history) HTN, recent smoker (40 pack year history) Peak trops = 620 Peak trops = 68 Peak trops = 108 Cath: Mild plaque No significant stenosis Cath: 90% stenosis ostial RCA; mild dz LAD/LCX Cardiac CT: Normal coronaries

slide-17
SLIDE 17
  • The size of the troponin elevation does not

correlate with extent of coronary disease But

  • The rise of the troponin does indicate poorer
  • utcome in patients compared to normal

troponin counterparts

Concept

slide-18
SLIDE 18

Ostermann et al. Critical Care 2014

slide-19
SLIDE 19
slide-20
SLIDE 20
slide-21
SLIDE 21

Lim et al, Arch Intern Med 2006

slide-22
SLIDE 22

Other Medical Conditions

Condition Hazard Ratio

Critical Illness OR 2.5 for all cause mortality Chronic Kidney Disease Trop T adjusted HR = 3 Trop I adjusted HR = 2.7 Pulmonary Embolism OR 4.8 for all cause mortality

slide-23
SLIDE 23

The Importance of Myocardial Injury

Devereaux, JAMA, 2012

slide-24
SLIDE 24

Approach

  • Look for and correct physiological abnormalities

– hypoxia, hypotension, tachycardia (if BP adequate), Hb if <70, sepsis, PE

  • If no signs of bleeding initiate ASA 81 mg daily
  • Initiate or intensify Statin therapy
  • Inpatient vs. outpatient risk stratification and follow up
slide-25
SLIDE 25

CASE 4: Postoperative troponin monitoring

  • 64 y/o male
  • Postop day 3 orthopedic surgery
  • No symptoms, trop 0.15 (0.04 ULN)
  • EKG: Anterior biphasic T waves
  • Cath/OCT - 3 days after trop increase
slide-26
SLIDE 26
  • 1. Normal coronaries
  • 2. Mild atherosclerotic plaque with no significant stenosis
  • 3. Single vessel disease with plaque rupture/thrombus
  • 4. Single vessel disease but no thrombus/stable plaque

This patient has:

slide-27
SLIDE 27

CASE 5: Perioperative Myocardial Infarction

  • 83 y/o male
  • Postop day 5 orthopedic surgery
  • Sudden chest pain trop 9.85 (0.04 ULN),
  • EKG: No acute changes
  • Cath/OCT - 2 days after trop increase
slide-28
SLIDE 28
  • 1. Normal coronaries
  • 2. Mild atherosclerotic plaque with no significant stenosis
  • 3. Single vessel disease with plaque rupture/thrombus
  • 4. Single vessel disease but no thrombus/stable plaque

This patient has:

slide-29
SLIDE 29

Summary of Cases 4 and 5

Case 4 Case 5 64 year old male 83 year old male POD 3 orthopedic surgery POD 5 orthopedic surgery No symptoms, trop 0.15 (ULN 0.04) Sudden chest pain, trops 9.85 (ULN 0.04) Biphasic T waves anterior leads No acute ECG changes

slide-30
SLIDE 30

Case 4 Cath Findings

slide-31
SLIDE 31

Case 4 OCT findings

slide-32
SLIDE 32

PCI with BMS, Dual antiplatelet therapy with ASA and Plavix for 1 year Uncomplicated course at 1 year

slide-33
SLIDE 33

CASE 5: Perioperative Myocardial Infarction

  • 83 y/o male
  • Postop day 5 orthopedic surgery
  • Sudden chest pain trop 9.85 (0.04 ULN),
  • EKG: No acute changes
  • Cath/OCT - 2 days after trop increase
slide-34
SLIDE 34

Case 5 Cath Findings

Moderate LAD stenosis Distal LCX stenosis >80% in small vessel Normal LV function

slide-35
SLIDE 35

Case 5 OCT findings

slide-36
SLIDE 36

PCI with BMS 3.5 mm Dual antiplatelet therapy x 12 months Uncomplicated course at 30 days

slide-37
SLIDE 37

Summary of Cases 4 and 5

Case 4 Case 5 64 year old male 83 year old male POD 3 orthopedic surgery POD 5 orthopedic surgery No symptoms, trop 0.15 (ULN 0.04) Sudden chest pain, trops 9.85 (ULN 0.04) Biphasic T waves anterior leads No acute ECG changes

slide-38
SLIDE 38

Summary of Cases 4 and 5

Case 4 Case 5 64 year old male 83 year old male POD 3 orthopedic surgery POD 5 orthopedic surgery No symptoms, trop 0.15 (ULN 0.04) Sudden chest pain, trops 9.85 (ULN 0.04) Biphasic T waves anterior leads No acute ECG changes Plaque rupture and thrombus - LAD Significant stenosis RCA but no plaque rupture

slide-39
SLIDE 39
  • The size of the troponin elevation does not

correlate pathophysiology

– i.e. cannot distinguish between plaque rupture vs. supply demand

  • Presence or absence of symptoms not helpful in

determining pathophysiology

– Further, no significant difference in mortality

  • utcomes

Concept

slide-40
SLIDE 40

MINS that probably will go undetected without trop monitoring

  • MINS without chest discomfort, other

possible symptoms (i.e., arm, neck, or jaw discomfort, shortness of breath), or pulmonary edema

  • 84.2%
slide-41
SLIDE 41

MINS – High Sensitivity Assay

  • Among 3904 patients who had MINS
  • 93.1% did not experience an ischemic symptom
  • 21.7% fulfilled universal definition of MI

– elevated hsTnT with ≥1 ischemic feature

  • Thus, troponin screening is the most effective way to screen

for cardiac complications

slide-42
SLIDE 42

Approach to MINS

  • Look for and correct physiological

abnormalities

– hypoxia, hypotension, tachycardia (if BP adequate), Hb if <70

  • If no signs of bleeding initiate ASA 81 mg daily
  • Initiate or intensify Statin therapy
slide-43
SLIDE 43

BNP/nt-pro BNP

  • Usage in diagnosis of CHF vs. Resp cause
  • Usage in prognosis of CHF and acute decomp
  • Usage in periop risk stratification
slide-44
SLIDE 44

Case 6

  • 67 M seen in preop for bariatric surgery
  • Cardiac RF: DM, HTN, remote smoker
  • Other PMHX: prev colon ca, OSA, GERD,

migraines

  • Meds: Rosuvastatin, Ramipril, Metformin,

Empagliflozin

  • “Asymptomatic” but nt-pro BNP = 219
slide-45
SLIDE 45

Nuclear Perfusion Study No Persantine ECG changes

slide-46
SLIDE 46

Nuclear Perfusion Study

slide-47
SLIDE 47

Nuclear Perfusion – PET/CT

slide-48
SLIDE 48

Cath

slide-49
SLIDE 49

Concept

  • For the vast majority of patients pre-op

BNP/nt-pro BNP will filter out low risk patients

  • Need for a patient centred approach when the

nt-pro BNP is abnormal

– Symptoms – Urgency of surgery – Awareness of risk involved – Patient preferences

slide-50
SLIDE 50

Summary

  • Patients with troponin elevation are prognostically at higher

risk of death at 180-365 days compared to their normal trop counterparts – Critical care, PE, CKD, Periop literature

  • Approach includes treating the underlying medical condition

– Initiating basic cardiovascular therapies such as ASA, statins – In/Outpatient risk stratification plan and followup

  • While for the vast majority, BNP/NT-proBNP will clear people

into lower risk categories

– Need a patient centred approach for when abnormal – Patient symptoms, urgency of surgery, risk involved, pt preferences

slide-51
SLIDE 51

CSIM Annual Meeting 2017

Special thanks to Dr. PJ Devereaux

  • Scientific Leader, Perioperative Research

Group, PHRI, McMaster University

  • VISION, POISE 1, POISE 2
  • MANAGE, HIP ATTACK, VISION 2, POISE 3
  • Co-Chair, CCS Perioperative Guidelines
slide-52
SLIDE 52

Questions and Comments